Search

Your search keyword '"Elsa Mondou"' showing total 51 results

Search Constraints

Start Over You searched for: Author "Elsa Mondou" Remove constraint Author: "Elsa Mondou" Topic medicine Remove constraint Topic: medicine
51 results on '"Elsa Mondou"'

Search Results

1. Immune globulin subcutaneous, human – klhw 20% for primary humoral immunodeficiency: an open-label, Phase III study

2. Safety and neutralizing rabies antibody in healthy subjects given a single dose of rabies immune globulin caprylate/chromatography purified

Catalog

Books, media, physical & digital resources

3. A Phase 3 Multicenter, Prospective, Open-Label Efficacy and Safety Study of Immune Globulin (Human) 10% Caprylate/Chromatography Purified in Patients with Myasthenia Gravis Exacerbations

4. Myasthenia gravis: Historical achievements and the 'golden age' of clinical trials

5. Gamunex® in Guillain-Barré Syndrome: A Postmarketing, Retrospective, Observational Study

6. Immune globulin subcutaneous, human – klhw 20% solution (Xembify®, IGSC-C 20%) has a positive safety and tolerability profile in an open-label, multicenter, phase 3 study in primary immunodeficiency (PI)

7. Immune globulin subcutaneous, human – klhw 20% solution (Xembify®, IGSC-C 20%) is effective in primary humoral immunodeficiency (PI): results from a prospective, open-label, multicenter, phase 3 study

8. Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus Infection

9. A phase 2a, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis

10. Sustained Hepatitis B e Antigen Seroconversion in Patients with Chronic Hepatitis B after Adefovir Dipivoxil Treatment: Analysis of Precore and Basal Core Promoter Mutants

11. Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B

12. Impact of Early Viral Kinetics on T-Cell Reactivity during Antiviral Therapy in Chronic Hepatitis B

13. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: A two-year study

14. Dose Range Study of Pharmacokinetics, Safety, and Preliminary Antiviral Activity of Emtricitabine in Adults with Hepatitis B Virus Infection

15. Posttreatment Exacerbation of Hepatitis B Virus (HBV) Infection in Long-Term HBV Trials of Emtricitabine

16. Safety and efficacy of ulimorelin administered postoperatively to accelerate recovery of gastrointestinal motility following partial bowel resection: results of two randomized, placebo-controlled phase 3 trials

17. Efficacy and safety of long-term adefovir dipivoxil therapy in children with chronic hepatitis B infection

18. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B

19. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease

20. Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B

21. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults

22. Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B

23. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B

24. A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV

25. A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B

26. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature

27. 1219 THREE-DAY, DOSE-RANGING STUDY OF THE HCV NS5A INHIBITOR GS-5885

28. 925 SAFETY AND TOLERABILITY OF 96 WEEKS OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN HBeAg NEGATIVE AND POSITIVE PATIENTS INFECTED WITH CHRONIC HEPATITIS B (CHB)

29. 21 TWO YEARS SAFETY AND EFFICACY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) IN PATIENTS WITH HBV-INDUCED CIRRHOSIS

30. 923 SAFETY AND EFFICACY OF 96 WEEKS OF TENOFOVIR DISOPROXIL FUMARATE THERAPY IN LAMIVUDINE EXPERIENCED PATIENTS

31. Mo2090 Gastric Emptying, Glycemia, and Upper GI Symptoms Are Independent Factors in Diabetic Gastroparesis

33. 84 SAFETY, TOLERABILITY AND PRELIMINARY ACTIVITY OF GS-9450, A SELECTIVE CASPASE INHIBITOR, IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH)

34. 1006 HBSAG KINETICS OF DECAY AND BASELINE CHARACTERISTICS OF HBEAG-POSITIVE PATIENTS WITH CHRONIC HEPATITIS B FOLLOWING 3 YEARS OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT

35. W1814 Safety and Tolerability of 96 Weeks of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg Negative and Positive Patients Infected with Chronic Hepatitis B (CHB)

36. 321 Safety and Efficacy of 96 Weeks of Tenofovir Disoproxil Fumarate Therapy in Lamivudine Experienced Patients

37. M1782 Characteristics of HBeAg-Positive Patients with HBsAg Loss/Seroconversion Following Treatment with Tenofovir Disoproxil Fumarate (TDF)

38. W1806 Two Years Safety and Efficacy of Tenofovir Disoproxil Fumarate (TDF) in Patients with HBV-Induced Cirrhosis

39. 909 CHARACTERISTICS OF HBeAg-POSITIVE PATIENTS WITH HBsAg LOSS/SEROCONVERSION FOLLOWING TREATMENT WITH TENOFOVIR DISOPROXIL FUMARATE (TDF)

40. 254 Tenofovir Disoproxil Fumarate (TDF) for the Treatment of HBeAg-Positive Chronic Hepatitis B: Week 72 TDF Data and Week 24 Adefovir Dipivoxil Switch Data (Study 103)

41. M1912 The Antiviral Response to Tenofovir Disoproxil Fumarate (TDF) Is Comparable in Lamivudine (LAM)-NaïVe and LAM-Experienced Subjects Treated for Chronic Hepatitis B (CHB)

42. M1910 Tenofovir Disoproxil Fumarate (TDF) Is Highly Active for Treatment of Chronic Hepatitis B in Subjects with Cirrhosis

43. 74 THE ANTIVIRAL RESPONSE TO TENOFOVIR DISOPROXIL FUMARATE (TDF) IS COMPARABLE IN LAMIVUDINE (LAM)-NAIVE AND LAM-EXPERIENCED SUBJECTS TREATED FOR CHRONIC HEPATITIS B (CHB)

44. 75 TENOFOVIR DISOPROXIL FUMARATE (TDF) IS HIGHLY ACTIVE FOR TREATMENT OF CHRONIC HEPATITIS B IN SUBJECTS WITH CIRRHOSIS

45. 57 TENOFOVIR DISOPROXIL FUMARATE (TDF) FOR THE TREATMENT OF HBEAG-NEGATIVE CHRONIC HEPATITIS B: WEEK 72 TDF DATA AND WEEK 24 ADEFOVIR DIPIVOXIL SWITCH DATA (STUDY 102)

46. 503 Durability of HBeAg seroconversion following adefovir dipivoxil treatment for chronic hepatitis B (CHB)

47. 494 Two-state modeling of virological and biochemical efficacy plus liver biopsies demonstrate efficacy of adefovir dipivoxil in HBeAg-negative chronic hepatitis B over four or five years

48. Efficacy and Safety of Emtricitabine vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients<SUBTITLE>A Randomized Trial</SUBTITLE>

49. A phase I/II dose escalating trial evaluating safety, tolerability, pharmacokinetics and antiviral activity of clevudine in patients chronically infected with HBV

50. A dose escalating trial evaluating the safety and antiviral activity of clevudine in patients with chronic HBV infection